middle.news
Vita Life Sciences Guides to Modest H1 2026 Growth Amid China Export Challenges
10:40am on Friday 12th of June, 2026 AEST
•
Healthcare
Read Story
Vita Life Sciences Guides to Modest H1 2026 Growth Amid China Export Challenges
10:40am on Friday 12th of June, 2026 AEST
Key Points
H1 2026 sales guidance of $46.3m-$47.3m
Pre-tax profit expected at $6.8m-$7.3m
Growth driven by Australia and Malaysia/Singapore
Reduced exports to China due to regulatory changes
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vita Life Sciences (ASX:VLS)
OPEN ARTICLE